About Oxford Immunotec Global PLC (NASDAQ:OXFD)
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company's product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology. Its T-SPOT.TB test is used to test for tuberculosis (TB), infection and leverages its T-SPOT technology platform, which allows it to measure the response of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. It offers a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. It has a series of assays for use in blood screening, building upon its expertise in tick-borne disease. Its T-SPOT. CMV and T-SPOT. PRT tests are part of its product line focused on the transplantation market.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Diagnostic & Testing Equipment
- Sub-Industry: N/A
- Symbol: NASDAQ:OXFD
- CUSIP: N/A
- Web: www.oxfordimmunotec.com
Capitalization:- Market Cap: $408.99 million
- Outstanding Shares: 25,514,000
Average Prices:- 50 Day Moving Avg: $16.22
- 200 Day Moving Avg: $15.72
- 52 Week Range: $11.88 - $19.51
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -17.86
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $97.44 million
- Price / Sales: 4.21
- Book Value: $2.28 per share
- Price / Book: 7.05
Profitability:- EBITDA: ($23,660,000.00)
- Net Margins: -34.58%
- Return on Equity: -35.76%
- Return on Assets: -21.67%
Debt:- Debt-to-Equity Ratio: 0.57%
- Current Ratio: 2.93%
- Quick Ratio: 2.51%
Misc:- Average Volume: 106,443 shs.
- Beta: -0.08
- Short Ratio: 8.72
Frequently Asked Questions for Oxford Immunotec Global PLC (NASDAQ:OXFD)
What is Oxford Immunotec Global PLC's stock symbol?
Oxford Immunotec Global PLC trades on the NASDAQ under the ticker symbol "OXFD."
How were Oxford Immunotec Global PLC's earnings last quarter?
Oxford Immunotec Global PLC (NASDAQ:OXFD) posted its quarterly earnings data on Tuesday, August, 1st. The company reported ($0.32) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.32). The firm had revenue of $26.10 million for the quarter, compared to analysts' expectations of $25.05 million. Oxford Immunotec Global PLC had a negative net margin of 34.58% and a negative return on equity of 35.76%. The business's quarterly revenue was up 35.9% on a year-over-year basis. During the same quarter last year, the company posted ($0.29) EPS. View Oxford Immunotec Global PLC's Earnings History.
When will Oxford Immunotec Global PLC make its next earnings announcement?
Where is Oxford Immunotec Global PLC's stock going? Where will Oxford Immunotec Global PLC's stock price be in 2017?
3 brokerages have issued twelve-month price objectives for Oxford Immunotec Global PLC's stock. Their forecasts range from $19.00 to $26.00. On average, they anticipate Oxford Immunotec Global PLC's stock price to reach $22.00 in the next twelve months. View Analyst Ratings for Oxford Immunotec Global PLC.
What are analysts saying about Oxford Immunotec Global PLC stock?
Here are some recent quotes from research analysts about Oxford Immunotec Global PLC stock:
- 1. According to Zacks Investment Research, "Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company's first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. " (10/4/2017)
- 2. BTIG Research analysts commented, "This evening bluebird provided a 1Q update via press release (no conference call, as usual). Following an April meeting with the EMA, BLUE updated its EU regulatory strategy noting that it anticipates filing for conditional approval in non-B0/B0 patients on the basis of the ongoing Northstar and HGB-205 studies, plus data available from the ongoing Northstar-2 at the time of filing. Amount of follow up needed from Northstar and HGB-205 is TBD (data dependent and discussions with the EMA are ongoing). On the catalyst front, previously announced timelines are intact, and 2017 is looking to be a busy year for bluebird. Overall, we remain encouraged with the company’s continued progress across multiple clinical programs involving its potentially transformative gene therapy and CAR-T platforms. Maintain OW." (5/4/2017)
Who are some of Oxford Immunotec Global PLC's key competitors?
Some companies that are related to Oxford Immunotec Global PLC include Heron Therapeutics (HRTX), PetIQ (PETQ), BeyondSpring (BYSI), ZIOPHARM Oncology (ZIOP), China Cord Blood Corporation (CO), Revance Therapeutics (RVNC), Cytokinetics, Incorporated (CYTK), AtriCure (ATRC), Alder BioPharmaceuticals (ALDR), Crispr Theraptc (CRSP), La Jolla Pharmaceutical Company (LJPC), Keryx Biopharmaceuticals (KERX), Eagle Pharmaceuticals (EGRX), Abeona Therapeutics (ABEO), CytomX Therapeutics (CTMX), PTC Therapeutics (PTCT), Vanda Pharmaceuticals (VNDA) and Coherus BioSciences (CHRS).
Who are Oxford Immunotec Global PLC's key executives?
Oxford Immunotec Global PLC's management team includes the folowing people:
- Richard A. Sandberg, Independent Chairman of the Board
- Peter James Wrighton-Smith Ph.D., Chief Executive Officer, Director
- Richard M. Altieri, Chief Financial Officer
- Stefan C. Linn, Chief Operating Officer
- Stephen M. Gansler, Senior Vice President and Global Head of Human Resources
- Peter Edwardson Ph.D., Senior Vice President & Head of Blood Screening
- Elizabeth M. Keiley, Vice President, General Counsel
- Jeff R. Schroeder, Chief Commercial Officer
- Richard Wenstrup M.D., Chief Medical Officer
- .. Scott .., Director
How do I buy Oxford Immunotec Global PLC stock?
Shares of Oxford Immunotec Global PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Oxford Immunotec Global PLC's stock price today?
One share of Oxford Immunotec Global PLC stock can currently be purchased for approximately $16.07.
MarketBeat Community Rating for Oxford Immunotec Global PLC (NASDAQ OXFD)MarketBeat's community ratings are surveys of what our community members think about Oxford Immunotec Global PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Oxford Immunotec Global PLC (NASDAQ:OXFD)Earnings History by Quarter for Oxford Immunotec Global PLC (NASDAQ OXFD)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/31/2017 | | ($0.17) | | | | | N/A |  |
| 8/1/2017 | Q2 2017 | ($0.32) | ($0.32) | $25.05 million | $26.10 million | View | Listen | |
| 5/2/2017 | 3/31/2017 | ($0.35) | ($0.36) | $21.17 million | $21.51 million | View | Listen | |
| 3/1/2017 | 12/31/2016 | ($0.39) | ($0.22) | $23.06 million | $23.71 million | View | Listen | |
| 11/1/2016 | Q316 | ($0.33) | ($0.18) | $24.79 million | $26.10 million | View | N/A | |
| 8/2/2016 | Q216 | ($0.33) | ($0.29) | $18.10 million | $19.20 million | View | N/A | |
| 5/3/2016 | Q116 | ($0.32) | ($0.32) | $16.96 million | $17.10 million | View | N/A | |
| 3/1/2016 | Q415 | ($0.28) | ($0.29) | $16.34 million | $16.00 million | View | N/A | |
| 11/3/2015 | Q315 | ($0.25) | ($0.20) | $17.31 million | $17.90 million | View | N/A | |
| 8/4/2015 | Q215 | ($0.34) | ($0.33) | $14.04 million | $14.30 million | View | N/A | |
| 5/5/2015 | Q115 | ($0.33) | ($0.31) | $13.35 million | $13.80 million | View | N/A | |
| 3/3/2015 | Q414 | ($0.44) | ($0.39) | $11.93 million | $12.10 million | View | N/A | |
| 11/4/2014 | Q314 | ($0.38) | ($0.35) | $12.85 million | $13.30 million | View | N/A | |
| 8/5/2014 | Q214 | ($0.20) | ($0.36) | $11.39 million | $11.80 million | View | N/A | |
| 5/6/2014 | Q114 | ($0.18) | ($0.18) | $11.64 million | $12.30 million | View | N/A | |
| 3/4/2014 | Q413 | ($0.19) | ($0.38) | $9.28 million | $10.20 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Oxford Immunotec Global PLC (NASDAQ:OXFD)Current Year EPS Consensus Estimate: $-1.56 EPS
Next Year EPS Consensus Estimate: $-0.9 EPS
Dividend History for Oxford Immunotec Global PLC (NASDAQ:OXFD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Oxford Immunotec Global PLC (NASDAQ:OXFD)Insider Ownership Percentage: 8.11%
Institutional Ownership Percentage: 79.21%
Insider Trades by Quarter for Oxford Immunotec Global PLC (NASDAQ:OXFD)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 10/2/2017 | Peter Wrighton-Smith | CEO | Sell | 55,000 | $16.78 | $922,900.00 | |
| 9/1/2017 | Richard A Sandberg | Director | Sell | 3,000 | $15.82 | $47,460.00 | |
| 8/15/2017 | Peter Edwardson | COO | Sell | 9,739 | $16.14 | $157,187.46 | |
| 8/7/2017 | Peter Edwardson | COO | Sell | 22,371 | $17.70 | $395,966.70 | |
| 7/6/2017 | Peter Wrighton-Smith | CEO | Sell | 27,168 | $15.94 | $433,057.92 | |
| 7/5/2017 | Peter Wrighton-Smith | CEO | Sell | 32,832 | $16.58 | $544,354.56 | |
| 6/28/2017 | Peter Wrighton-Smith | CEO | Sell | 30,000 | $16.06 | $481,800.00 | |
| 6/15/2017 | Elizabeth M Keiley | VP | Sell | 4,085 | $15.01 | $61,315.85 | |
| 5/15/2017 | Peter Edwardson | COO | Sell | 10,000 | $14.66 | $146,600.00 | |
| 5/10/2017 | Richard A Sandberg | Director | Sell | 3,000 | $14.40 | $43,200.00 | |
| 5/9/2017 | Jeff R Schroeder | Insider | Sell | 40,000 | $14.14 | $565,600.00 | |
| 4/3/2017 | Peter Wrighton-Smith | CEO | Sell | 30,000 | $15.43 | $462,900.00 | |
| 4/3/2017 | Richard A Sandberg | Director | Sell | 3,000 | $15.47 | $46,410.00 | |
| 3/20/2017 | Elizabeth M Keiley | VP | Sell | 3,000 | $16.05 | $48,150.00 | |
| 2/6/2017 | Peter Wrighton-Smith | CEO | Sell | 25,000 | $13.36 | $334,000.00 | |
| 12/16/2016 | Peter Wrighton-Smith | CEO | Sell | 7,052 | $15.07 | $106,273.64 | |
| 12/5/2016 | Peter Wrighton-Smith | CEO | Sell | 1,140 | $15.00 | $17,100.00 | |
| 12/2/2016 | Peter Wrighton-Smith | CEO | Sell | 61,808 | $15.00 | $927,120.00 | |
| 11/8/2016 | Richard A Sandberg | Director | Sell | 12,000 | $14.17 | $170,040.00 | |
| 11/18/2015 | Richard A. Sandberg | Director | Sell | 5,000 | $13.48 | $67,400.00 | |
| 11/17/2015 | Richard A. Sandberg | Director | Sell | 5,000 | $13.00 | $65,000.00 | |
| 6/16/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 41,230 | $14.30 | $589,589.00 | |
| 6/15/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 1,529 | $14.27 | $21,818.83 | |
| 6/12/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 31,598 | $14.27 | $450,903.46 | |
| 6/10/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 24,649 | $14.28 | $351,987.72 | |
| 6/9/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 13,000 | $14.26 | $185,380.00 | |
| 6/8/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 2,662 | $14.25 | $37,933.50 | |
| 6/3/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 36,474 | $14.29 | $521,213.46 | |
| 6/1/2015 | Richard A Sandberg | Director | Sell | 3,000 | $14.14 | $42,420.00 | |
| 3/23/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 53,415 | $14.49 | $773,983.35 | |
| 3/19/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 154,319 | $14.65 | $2,260,773.35 | |
| 1/14/2015 | Richard A Sandberg | Director | Sell | 3,000 | $14.00 | $42,000.00 | |
| 12/5/2014 | Patricia Randall | Director | Sell | 5,000 | $12.06 | $60,300.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Oxford Immunotec Global PLC (NASDAQ:OXFD)
Latest Headlines for Oxford Immunotec Global PLC (NASDAQ:OXFD)
| Source: |
|
| Date | Headline |
|---|
 | Oxford Immunotec Global Plc breached its 50 day moving average in a Bearish Manner : OXFD-US : October 20, 2017
finance.yahoo.com - October 21 at 7:49 AM |
 | Oxford Immunotec Schedules Third Quarter 2017 Earnings Release and Conference Call for October 31,
www.nasdaq.com - October 17 at 3:48 PM |
| Oxford Immunotec Schedules Third Quarter 2017 Earnings Release and Conference Call for October 31, 2017
finance.yahoo.com - October 17 at 3:48 PM |
 | Oxford Immunotec Global PLC (OXFD) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - October 17 at 2:52 AM |
| Oxford Immunotec Global PLC (OXFD) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - October 8 at 9:56 PM |
| Analysts Anticipate Oxford Immunotec Global PLC (OXFD) Will Announce Quarterly Sales of $30.11 Million
www.americanbankingnews.com - October 6 at 6:44 AM |
| Oxford Immunotec Global PLC (OXFD) CEO Sells $922,900.00 in Stock
www.americanbankingnews.com - October 4 at 7:40 PM |
| Oxford Immunotec Global PLC (OXFD) Expected to Announce Earnings of -$0.25 Per Share
www.americanbankingnews.com - October 4 at 2:36 PM |
| Oxford Immunotec Global PLC (OXFD) Receives Buy Rating from Cowen and Company
www.americanbankingnews.com - September 28 at 9:32 PM |
| Oxford Immunotec Global PLC (OXFD) Coverage Initiated by Analysts at BTIG Research
www.americanbankingnews.com - September 28 at 8:20 PM |
 | Benzinga's Top Upgrades, Downgrades For September 28, 2017 - Benzinga
www.benzinga.com - September 28 at 7:27 PM |
 | Oxford loses bid to prevent Qiagen from selling QFT-Plus TB test before patent infringement trial, but likely to ... - Seeking Alpha
seekingalpha.com - September 28 at 7:27 PM |
 | Oxford Immunotec Announces Update in Patent Infringement Litigation - GlobeNewswire (press release)
globenewswire.com - September 28 at 7:27 PM |
| Oxford Immunotec Global PLC (OXFD) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - September 22 at 2:34 AM |
| Head to Head Analysis: Oxford Immunotec Global PLC (OXFD) and Varex Imaging (VREX)
www.americanbankingnews.com - September 11 at 2:18 PM |
| Oxford Immunotec Global PLC (OXFD) Director Sells $47,460.00 in Stock
www.americanbankingnews.com - September 5 at 8:32 PM |
| Contrasting VAREX IMAGING (VREX) & Oxford Immunotec Global PLC (OXFD)
www.americanbankingnews.com - September 1 at 10:34 AM |
| Oxford Immunotec to Present at the Baird 2017 Global Healthcare Conference
finance.yahoo.com - August 31 at 8:30 AM |
| -$0.25 Earnings Per Share Expected for Oxford Immunotec Global PLC (OXFD) This Quarter
www.americanbankingnews.com - August 28 at 10:40 AM |
| Oxford Immunotec Global PLC (OXFD) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 28 at 2:36 AM |
| Cowen and Company Lowers Oxford Immunotec Global PLC (OXFD) Price Target to $19.00
www.americanbankingnews.com - August 17 at 4:20 PM |
| Oxford Immunotec Global Plc breached its 50 day moving average in a Bearish Manner : OXFD-US : August 16, 2017
finance.yahoo.com - August 17 at 6:39 AM |
| Oxford Immunotec Global PLC (OXFD) COO Peter Edwardson Sells 9,739 Shares
www.americanbankingnews.com - August 16 at 8:46 PM |
| Oxford Immunotec Global PLC Announces Pricing of Underwritten Public Offering of Ordinary Shares
finance.yahoo.com - August 16 at 6:34 AM |
 | Oxford Immunotec (OXFD) to Sell 2.5M Ordinary Shares
www.streetinsider.com - August 15 at 6:03 AM |
| Oxford Immunotec (OXFD) to Sell 2.5M Ordinary Shares
www.streetinsider.com - August 15 at 6:03 AM |
| Oxford Immunotec Global PLC Announces Agreement to Sell 2,500,000 Ordinary Shares
finance.yahoo.com - August 15 at 6:03 AM |
| Oxford Immunotec Global PLC Announces Agreement to Sell 2,500,000 Ordinary Shares
finance.yahoo.com - August 15 at 6:03 AM |
| Alphatec Holdings (ATEC) & Oxford Immunotec Global PLC (OXFD) Critical Comparison
www.americanbankingnews.com - August 14 at 4:22 AM |
| Analysts Anticipate Oxford Immunotec Global PLC (OXFD) to Announce -$0.22 Earnings Per Share
www.americanbankingnews.com - August 10 at 12:28 AM |
| Oxford Immunotec Global PLC (NASDAQ:OXFD) COO Peter Edwardson Sells 22,371 Shares
www.americanbankingnews.com - August 9 at 8:44 PM |
| HTG Molecular Diagnostics (HTGM) versus Oxford Immunotec Global PLC (NASDAQ:OXFD) Head-To-Head Review
www.americanbankingnews.com - August 3 at 2:26 PM |
| Oxford Immunotec Global PLC (NASDAQ:OXFD) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - August 3 at 12:38 PM |
| Oxford Immunotec Global Plc :OXFD-US: Earnings Analysis: Q2, 2017 By the Numbers : August 2, 2017
finance.yahoo.com - August 3 at 6:43 AM |
| Oxford Immunotec Global PLC (NASDAQ:OXFD) Given Consensus Recommendation of "" by Analysts
www.americanbankingnews.com - August 2 at 10:32 AM |
| Oxford Immunotec Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 2 at 6:44 AM |
| Edited Transcript of OXFD earnings conference call or presentation 1-Aug-17 12:00pm GMT
finance.yahoo.com - August 2 at 6:44 AM |
| Oxford Immunotec reports 2Q loss
finance.yahoo.com - August 2 at 6:44 AM |
| Oxford Immunotec Global PLC (NASDAQ:OXFD) Issues Earnings Results
www.americanbankingnews.com - August 1 at 2:20 PM |
| Reviewing Cepheid (CPHD) and Oxford Immunotec Global PLC (OXFD)
www.americanbankingnews.com - July 27 at 4:25 PM |
| Oxford Immunotec Global PLC (OXFD) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - July 27 at 2:39 PM |
| Oxford Immunotec (OXFD) Appoints Richard Wenstrup as CMO
www.streetinsider.com - July 25 at 5:41 AM |
| Oxford Immunotec Appoints Richard Wenstrup, MD, as Chief Medical Officer
finance.yahoo.com - July 24 at 2:35 PM |
| Analysts Anticipate Oxford Immunotec Global PLC (OXFD) Will Announce Quarterly Sales of $25.30 Million
www.americanbankingnews.com - July 22 at 8:50 AM |
| -$0.32 EPS Expected for Oxford Immunotec Global PLC (NASDAQ:OXFD) This Quarter
www.americanbankingnews.com - July 20 at 6:24 PM |
| Oxford Immunotec Schedules Second Quarter 2017 Earnings Release and Conference Call for August 1, 2017
finance.yahoo.com - July 19 at 1:31 AM |
| Comparing WaferGen Bio-systems (WGBS) & Oxford Immunotec Global PLC (NASDAQ:OXFD)
www.americanbankingnews.com - July 16 at 10:28 PM |
| Oxford Immunotec Global PLC (OXFD) CEO Sells $433,057.92 in Stock
www.americanbankingnews.com - July 10 at 8:13 PM |
| Oxford Immunotec Global PLC (OXFD) CEO Sells $544,354.56 in Stock
www.americanbankingnews.com - July 7 at 8:16 PM |
| Analyzing HTG Molecular Diagnostics (HTGM) & Oxford Immunotec Global PLC (OXFD)
www.americanbankingnews.com - July 6 at 12:32 AM |
Oxford Immunotec Global PLC (OXFD) Chart for Saturday, October, 21, 2017
